These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 29583083)

  • 1. Postmenopausal Osteoporosis: A Clinical Review.
    Watts NB
    J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk following intermission of osteoporosis therapy.
    Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
    Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Practice. Postmenopausal Osteoporosis.
    Black DM; Rosen CJ
    N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinician's guide to prevention and treatment of osteoporosis.
    LeBoff MS; Greenspan SL; Insogna KL; Lewiecki EM; Saag KG; Singer AJ; Siris ES
    Osteoporos Int; 2022 Oct; 33(10):2049-2102. PubMed ID: 35478046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy.
    Silverman SL; Komm BS; Mirkin S
    Maturitas; 2014 Nov; 79(3):241-7. PubMed ID: 25124532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
    Anastasilakis AD; Polyzos SA; Makras P
    Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteoporosis in menopausal women between 40 and 65 years old : an algorithm for the gynaecologist].
    Surbone A; Vulliemoz N; Gonzalez-Rodriguez E; Chatelain JP; Lamy O
    Rev Med Suisse; 2016 Oct; 12(536):1811-1815. PubMed ID: 28692232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
    Chandran T; Venkatachalam I
    Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
    Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
    Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
    Wu J; Zhang Q; Yan G; Jin X
    J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.